Experience of observing patients with Duchenne myopathy

Duchenne muscular dystrophy is a genetically determined fatal disease with a steadily progressive course. It is characterized by the absence or sharp decrease (less than 3 % of the norm) of the dystrophin protein. In recent years, several drugs for pathogenetic treatment of Duchenne myodystrophy hav...

Full description

Saved in:
Bibliographic Details
Published inRusskiĭ zhurnal detskoĭ nevrologii Vol. 18; no. 2-3; pp. 31 - 37
Main Authors Minaycheva, L. I., Petlina, E. Yu, Ravzhaeva, E. G., Seitova, G. N.
Format Journal Article
LanguageEnglish
Russian
Published ABV-press 04.12.2023
Subjects
dmd gene
duchenne myopathy
dystrophin
exon skipping
pathogenetic therapy
Online AccessGet full text

Cover

More Information
Summary:Duchenne muscular dystrophy is a genetically determined fatal disease with a steadily progressive course. It is characterized by the absence or sharp decrease (less than 3 % of the norm) of the dystrophin protein. In recent years, several drugs for pathogenetic treatment of Duchenne myodystrophy have appeared in Russia. Unfortunately, this therapy is not universal and can only be prescribed to patients with certain types and regions of mutations. Establishing an accurate diagnosis for patients will allow timely determination of observation tactics, effective implementation of preventive and rehabilitative measures, and obtaining pathogenetic treatment. Gene therapy is a perspective option. This article describes clinical cases of Duchenne myopathy in patients with different variants of mutations in the dystrophin gene against the background of pathogenetic therapy.
ISSN:2073-8803
2412-9178
DOI:10.17650/2073-8803-2023-18-2-3-3-31-37